Pegfilgrastim Biosimilars Market 2022 - By Application (Chemotherapy Induced Neutropenia, Transplantation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030

Starting Price : $5000.00 | Pages : 223 | Published : January 2022 | SKU CODE : o&s198 | | Format :

Request Sample

Pegfilgrastim Biosimilars Market Definition

The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that use them for the treatment of febrile neutropenia – a life-threatening complication of cancer chemotherapy and to increase the production of infection-fighting white blood cells following transplantation. It is a recombinant human granulocyte colony stimulating factor (G-CSF) and helps to stimulate the production of infection-fighting white blood cells (neutrophils) for the treatment of cancer patients undergoing chemotherapy.  The drug has further applications where protection from infections where immune system is compromised, such as in bone marrow transplants.

Pegfilgrastim Biosimilars Market Size

The global pegfilgrastim biosimilars market reached a value of nearly $902.1 million in 2020. The pegfilgrastim biosimilars market is expected to grow from $902.1 million in 2020 to $1,801.0 million in 2025 at a rate of 14.8%. The growth in the pegfilgrastim biosimilars market is mainly due to an increased prevalence of cancer and increasing adoption of the biosimilars. The pegfilgrastim biosimilars market is then expected to grow at a CAGR of 17.5% from 2025 and reach $4,037.1 million in 2030.  

Growth in the historic period in the pegfilgrastim biosimilars market resulted from increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical R&D expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs. The pegfilgrastim biosimilars market was restrained by challenges due to regulatory changes, low number of drug approvals, lack of awareness on biosimilars among primary care physicians and specialists, and low healthcare access.

Going forward, increasing prevalence of cancer, aging population, increasing number of approvals, and targets and incentives are expected to drive the market. Factors that could hinder the growth of the pegfilgrastim biosimilars market in the future include effect of COVID-19, stringent regulations related to biosimilar approvals, and prolonged production and approval time.

Pegfilgrastim Biosimilars Market Drivers

The key drivers of the pegfilgrastim biosimilars market include:

Increase in Cancer Incidence Rate

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the pegfilgrastim biosimilars market during the forecast period. The incidence of cancer rises dramatically with age, most likely due to a build-up of risks for specific cancers that increase with age.  The International Agency for Research on Cancer (IARC) estimates that globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. According to the GLOBOCAN, nearly 19.3 million cases and 10 million cancer deaths were recorded in 2020.  Pegfilgrastim biosimilars help in producing white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, pegfilgrastim biosimilars accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infection after certain forms of treatment for cancer. Therefore, the increasing prevalence of cancer is expected to drive the growth of the pegfilgrastim biosimilars market.

Pegfilgrastim Biosimilars Market Restraints

The key restraints on the pegfilgrastim biosimilars market include:

Stringent Regulations Related To Biosimilar Approvals

Stringent regulations imposed on approvals of biosimilars is anticipated to hinder the growth of the pegfilgrastim biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In May 2021, out of the total 29 approved biosimilars by FDA, only 20 biosimilars were launched.  The robust government policies for approval of these drugs negatively impact manufacturers in the pegfilgrastim biosimilar market.

Pegfilgrastim Biosimilars Market Trends

Major trends influencing the pegfilgrastim biosimilars market include:

Revised FDA Regulations To Facilitate Biosimilar Drug Development

The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics and biosimilar requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics/biosimilar, can now be obtained from sources other than the FDA’s Center for Biologics Evaluation and Research (CBER), or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens. In addition, the FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products.

Robust Research & Development

The pegfilgrastim biosimilar market is witnessing robust research and development activities. These research and development activities have led to increasing success rates in clinical trials for biosimilars. Research and development is being carried out by market leaders in the biosimilars market as they continuously strive to make breakthroughs in the market in the form of new and effective biosimilars. For instance, Fresenius Kabi is developing MSB11455, a biosimilar which stimulates the growth of white blood cells that are essential to fight infections, a common adverse event in patients receiving chemotherapy for cancer. MSB11455 was developed in Switzerland by Fresenius Kabi’s immunology and oncology research lab.  Currently, the drug is in Phase I clinical study for oncology patients.  In June 2020, Pfizer, an American multinational pharmaceutical company, received approval from the US Food and Drug Administration to introduce its biosimilar drug for lowering the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs.  In June 2021, the FDA accepted the biologics license application (BLA) for biosimilar for pegfilgrastim proposed by Lupin Limited. The acceptance of the license has allowed Lupin to increase their product deliverables to various areas of medical needs. The FDA approved BLA has helped the company to expand their oncology portfolio and introduce affordable biologic options to patients.

Opportunities And Recommendations In The Pegfilgrastim Biosimilars Market

Opportunities –The top opportunities in the pegfilgrastim biosimilars market segmented by application will arise in the chemotherapy induced neutropenia segment, which will gain $701.0 million of global annual sales by 2025. The top opportunities in the pegfilgrastim biosimilars market segmented by distribution channel will arise in hospital pharmacies segment, which will gain $612.3 million of global annual sales by 2025. The pegfilgrastim biosimilars market size will gain the most in the USA at $426.9 million.

Recommendations-To take advantage of the opportunities, The Business Research Company recommends the pegfilgrastim biosimilars companies to focus on robust research & development, focus on strategic partnerships for new product development, set up authorized distributors and sales representatives, provide competitively priced offerings in low-income countries, increase visibility through business websites and healthcare websites, focus on increasing awareness, targeting hospitals and pharmacies to spread awareness, focus on patients suffering from cancer.

Pegfilgrastim Biosimilars Market Segmentation

The pegfilgrastim biosimilars market is segmented by application and by distribution channel
By Application–
The pegfilgrastim biosimilars market is segmented by application into
    • a) Chemotherapy Induced Neutropenia
    • b) Transplantation
    • c) Others
The chemotherapy induced neutropenia was the largest segment of the pegfilgrastim biosimilars market segmented by application, accounting for 75.5% of the total in 2020. Going forward, the chemotherapy induced neutropenia segment is expected to be the fastest growing segment in the pegfilgrastim biosimilars market segmented by therapy type, at a CAGR of 15.2% during 2020-2025.
By Distribution Channel –
The pegfilgrastim biosimilars market is segmented by distribution channel into
    • a) Hospital Pharmacies
    • b) Retail Pharmacies
    • c) Mail Order Pharmacies
The hospital pharmacies was the largest segment of the pegfilgrastim biosimilars market segmented by distribution channel, accounting for 87.7% of the total in 2020. Going forward, the mail order pharmacies segment is expected to be the fastest growing segment in the pegfilgrastim biosimilars market segmented by distribution channel, at a CAGR of 31.8% during 2020-2025.
By Geography - The pegfilgrastim biosimilars market is segmented by geography into
      o Asia Pacific
      • • China
      • • India
      • • Japan
      • • Australia
      • • Indonesia
      • • South Korea
      o North America
      • • USA
      o South America
      • • Brazil
      o Western Europe
      • • France
      • • Germany
      • • UK
      o Eastern Europe
      • • Russia
      o Middle East
      o Africa
North America was the largest region in the pegfilgrastim biosimilars market, accounting for 51.2% of the total in 2020. It was followed by the Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the pegfilgrastim biosimilars market will be Asia Pacific and North America where growth will be at CAGRs of 43.6% and 14.9% respectively.

Pegfilgrastim Biosimilars Competitive Landscape

Major Competitors are:

  • Coherus BioSciences
  • Sandoz (Novartis)
  • Biocon/Mylan
  • Intas Biopharmaceuticals Ltd
  • Mundipharma GmbH
  • Other Competitors Include:

  • Dr. Reddy's Laboratories
  • Pfizer Inc.
  • Emcure Pharmaceuticals
  • USV Private Limited
  • Apotex Pty Ltd
  • Kyowa Kirin Co. Ltd
  • Qilu Pharmaceutical
  • Gennova Biopharmaceuticals Limited
  • Lupin Limited
  • Pfizer
  • Fresenius Kabi
  • Napp Pharmaceuticals
  • Amega Biotech
    1. Table Of Contents

      1. Pegfilgrastim Biosimilars Market Executive Summary

      2. Table of Contents

      3. List of Figures

      4. List of Tables

      5. Report Structure

      6. Introduction

      6.1. Segmentation By Geography

      6.2. Segmentation By Application

      6.3. Segmentation By Distribution Channel

      7. Pegfilgrastim Biosimilars Market Characteristics

      7.1. Market Definition

      7.2. Market Segmentation By Application

      7.2.1. Chemotherapy Induced Neutropenia

      7.2.2. Transplantation

      7.2.3. Others

      7.3. Market Segmentation By Distribution Channel

      7.3.1. Hospital Pharmacies

      7.3.2. Retail Pharmacies

      7.3.3. Mail Order Pharmacies

      8. Pegfilgrastim Biosimilars Market Trends And Strategies

      8.1. Revised FDA Regulations To Facilitate Biosimilar Drug Development

      8.2. Robust Research & Development

      8.3. Large Number Of Strategic Partnerships

      8.4. Growing Mergers And Acquisitions

      8.5. Demand For Biosimilars In The Treatment Of Neutropenia

      9. Impact Of COVID-19 On Pegfilgrastim Biosimilars Market

      9.1. Impact On Global Pegfilgrastim Biosimilars Market

      9.2. Clinical Trial Delays

      9.3. Impact On Patients

      9.4. Impact On Major Players

      9.5. Future Outlook

      10. Global Pegfilgrastim Biosimilars Market Size And Growth

      10.1. Market Size

      10.2. Historic Market Growth, 2015 – 2020, Value ($ Million)

      10.2.1. Drivers Of The Market 2015 – 2020

      10.2.2. Restraints On The Market 2015 – 2020

      10.3. Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      10.3.1. Drivers Of The Market 2020 – 2025

      10.3.2. Restraints On The Market 2020 – 2025

      11. Global Pegfilgrastim Biosimilars Market Segmentation

      11.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      11.1.1. Chemotherapy Induced Neutropenia

      11.1.2. Transplantation

      11.1.3. Others

      11.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      11.2.1. Hospital Pharmacies

      11.2.2. Retail Pharmacies

      11.2.3. Mail-Order Pharmacies

      12. Pegfilgrastim Biosimilars Market, Regional And Country Analysis

      12.1. Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      12.2. Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13. Asia-Pacific Pegfilgrastim Biosimilars Market

      13.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview

      13.1.1. Region Information

      13.1.2. Market Information

      13.1.3. Background Information

      13.1.4. Government Initiatives

      13.1.5. Regulations

      13.1.6. Regulatory Bodies

      13.1.7. Major Associations

      13.1.8. Taxes Levied

      13.1.9. Corporate Tax Structure

      13.1.10. Investments

      13.1.11. Major Companies

      13.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.3. Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.4. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.5. Asia-Pacific Pegfilgrastim Biosimilars Market: Country Analysis

      13.6. China Pegfilgrastim Biosimilars Market

      13.7. China Pegfilgrastim Biosimilars Market Overview

      13.7.1. Country Information

      13.7.2. Market Information

      13.7.3. Background Information

      13.7.4. Government Initiatives

      13.7.5. Regulations

      13.7.6. Regulatory Bodies

      13.7.7. Major Associations

      13.7.8. Taxes Levied

      13.7.9. Corporate Tax Structure

      13.7.10. Investments

      13.7.11. Major Companies

      13.8. China Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.9. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.10. India Pegfilgrastim Biosimilars Market

      13.11. India Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.12. India Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.13. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.14. Japan Pegfilgrastim Biosimilars Market

      13.15. Japan Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.16. Japan Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.17. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.18. Australia Pegfilgrastim Biosimilars Market

      13.19. Australia Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.20. Australia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.21. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.22. Indonesia Pegfilgrastim Biosimilars Market

      13.23. Indonesia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.24. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.25. South Korea Pegfilgrastim Biosimilars Market

      13.26. South Korea Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.27. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14. Western Europe Pegfilgrastim Biosimilars Market

      14.1. Western Europe Pegfilgrastim Biosimilars Market Overview

      14.1.1. Region Information

      14.1.2. Market Information

      14.1.3. Background Information

      14.1.4. Government Initiatives

      14.1.5. Regulations

      14.1.6. Regulatory Bodies

      14.1.7. Major Associations

      14.1.8. Taxes levied

      14.1.9. Corporate Tax Structure

      14.1.10. Investments

      14.1.11. Major Companies

      14.2. Western Europe Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.3. Western Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.4. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14.5. Western Europe Pegfilgrastim Biosimilars Market: Country Analysis

      14.6. UK Pegfilgrastim Biosimilars Market

      14.7. UK Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.8. UK Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.9. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14.10. Germany Pegfilgrastim Biosimilars Market

      14.11. Germany Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.12. Germany Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.13. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14.14. France Pegfilgrastim Biosimilars Market

      14.15. France Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.16. France Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.17. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      15. Eastern Europe Pegfilgrastim Biosimilars Market

      15.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview

      15.1.1. Region Information

      15.1.2. Market Information

      15.1.3. Background Information

      15.1.4. Government Initiatives

      15.1.5. Regulations

      15.1.6. Regulatory Bodies

      15.1.7. Major Associations

      15.1.8. Taxes levied

      15.1.9. Corporate Tax Structure

      15.1.10. Investments

      15.1.11. Major Companies

      15.2. Eastern Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      15.3. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      15.4. Eastern Europe Pegfilgrastim Biosimilars Market: Country Analysis

      15.5. Russia Pegfilgrastim Biosimilars Market

      15.6. Russia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      15.7. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      16. North America Pegfilgrastim Biosimilars Market

      16.1. North America Pegfilgrastim Biosimilars Market Overview

      16.1.1. Region Information

      16.1.2. Market Information

      16.1.3. Background Information

      16.1.4. Government Initiatives

      16.1.5. Regulations

      16.1.6. Regulatory Bodies

      16.1.7. Major Associations

      16.1.8. Taxes Levied

      16.1.9. Corporate Tax Structure

      16.1.10. Investments

      16.1.11. Major Companies

      16.2. North America Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      16.3. North America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      16.4. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      16.5. North America Pegfilgrastim Biosimilars Market: Country Analysis

      16.6. USA Pegfilgrastim Biosimilars Market

      16.7. USA Pegfilgrastim Biosimilars Market Overview

      16.7.1. Country Information

      16.7.2. Market Information

      16.7.3. Background Information

      16.7.4. Government Initiatives

      16.7.5. Regulations

      16.7.6. Regulatory Bodies

      16.7.7. Major Associations

      16.7.8. Taxes Levied

      16.7.9. Corporate Tax Structure

      16.7.10. Investments

      16.7.11. Major Companies

      16.8. USA Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      16.9. USA Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      16.10. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      17. South America Pegfilgrastim Biosimilars Market

      17.1. South America Pegfilgrastim Biosimilars Market Overview

      17.1.1. Region Information

      17.1.2. Market Information

      17.1.3. Background Information

      17.1.4. Government Initiatives

      17.1.5. Regulations

      17.1.6. Regulatory Bodies

      17.1.7. Major Associations

      17.1.8. Taxes Levied

      17.1.9. Corporate Tax Structure

      17.1.10. Investments

      17.1.11. Major Companies

      17.2. South America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      17.3. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      17.4. South America Pegfilgrastim Biosimilars Market: Country Analysis

      17.5. Brazil Pegfilgrastim Biosimilars Market

      17.6. Brazil Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      17.7. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      18. Middle East Pegfilgrastim Biosimilars Market

      18.1. Middle East Pegfilgrastim Biosimilars Market Overview

      18.1.1. Region Information

      18.1.2. Market Information

      18.1.3. Background Information

      18.1.4. Government Initiatives

      18.1.5. Regulations

      18.1.6. Regulatory Bodies

      18.1.7. Major Associations

      18.1.8. Taxes levied

      18.1.9. Corporate Tax Structure

      18.1.10. Investments

      18.1.11. Major Companies

      18.2. Middle East Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      18.3. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      19. Africa Pegfilgrastim Biosimilars Market

      19.1. Africa Pegfilgrastim Biosimilars Market Overview

      19.1.1. Region Information

      19.1.2. Market Information

      19.1.3. Background Information

      19.1.4. Government Initiatives

      19.1.5. Regulations

      19.1.6. Regulatory Bodies

      19.1.7. Major Associations

      19.1.8. Taxes Levied

      19.1.9. Corporate Tax Structure

      19.1.10. Investments

      19.1.11. Major Companies

      19.2. Africa Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      19.3. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      20. Global Pegfilgrastim Biosimilars Market Competitive Landscape

      20.1. Company Profiles

      20.2. Coherus Biosciences Inc.

      20.2.1. Company Overview

      20.2.2. Products And Services

      20.2.3. Business Strategy

      20.2.4. Financial Overview

      20.3. Sandoz (Novartis)

      20.3.1. Company Overview

      20.3.2. Products And Services

      20.3.3. Business Strategy

      20.3.4. Financial Overview

      20.4. Biocon

      20.4.1. Company Overview

      20.4.2. Products And Services

      20.4.3. Business Strategy

      20.4.4. Financial Overview

      20.5. Mylan

      20.5.1. Company Overview

      20.5.2. Products And Services

      20.5.3. Business Strategy

      20.5.4. Financial Overview

      20.6. Intas Biopharmaceuticals Ltd

      20.6.1. Company Overview

      20.6.2. Products And Services

      20.6.3. Business Strategy

      20.6.4. Financial Overview

      20.7. Mundipharma GmbH

      20.7.1. Company Overview

      20.7.2. Products And Services

      20.7.3. Business Strategy

      20.7.4. Financial Overview

      20.8. Dr. Reddy’s Laboratories

      20.8.1. Company Overview

      20.8.2. Products And Services

      20.8.3. Business Strategy

      20.8.4. Financial Overview

      20.9. Pfizer Inc.

      20.9.1. Company Overview

      20.9.2. Products And Services

      20.9.3. Business Strategy

      20.9.4. Financial Overview

      20.10. Emcure Pharmaceuticals (Gennova Biopharmaceuticals Ltd.)

      20.10.1. Company Overview

      20.10.2. Products And Services

      20.10.3. Financial Overview

      20.11. USV Private Limited

      20.11.1. Company Overview

      20.11.2. Products And Services

      20.11.3. Business Strategy

      20.11.4. Financial Overview

      21. Pegfilgrastim Biosimilars Market Pipeline Analysis

      22. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

      22.1. AbCellera Acquired TetraGenetics

      22.2. Ligand Pharmaceuticals Acquired Pfenex

      22.3. True North Acquired Stake In Biocon Biologics

      22.4. Coherus BioSciences Inc Acquired Innovent Biologics Co. Ltd.

      22.5. Biocon Acquires Pfizer's R&D Facility To Boost Biosimilars Development

      22.6. AbbVie Acquired Allergan

      22.7. Kashiv Pharma Acquired Adello Biologics

      22.8. Mundipharma International Limited Acquired Cinfa Biotech

      22.9. Biocon Merged With Sandoz

      22.10. Fresenius Kabi Acquired The Biosimilars Business Of Merck KGaA

      23. Pegfilgrastim Biosimilars Market Future Outlook and Potential Analysis

      23.1. Global Pegfilgrastim Biosimilars Market In 2025 – Countries Offering Most New Opportunities

      23.2. Global Pegfilgrastim Biosimilars Market In 2025 – Segments Offering Most New Opportunities

      23.3. Global Pegfilgrastim Biosimilars Market In 2025 – Growth Strategies

      23.3.1. Market Trend Based Strategies

      23.3.2. Competitor Strategies

      24. Appendix

      24.1. Market Data Sources

      24.2. Research Methodology

      24.3. Currencies

      24.4. Research Inquiries

      24.5. The Business Research Company

      24.6. Copyright and Disclaimer

    List Of Tables

      Table 1: Global Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 2: Global Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 5: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 6: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 7: Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 8: Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 9: Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 10: Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 11: Asia Pacific Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
    • Table 12: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 13:  Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 14: Asia Pacific Per Capita Net Disposable Income, 2015-2020, $
    • Table 15: Asia-Pacific, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 16: Asia Pacific GDP Per Capita, 2015-2020, $
    • Table 17: Asia-Pacific, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 18: Asia-Pacific Biologics Market Size, 2015-2025, $ Billion
    • Table 19: Asia-Pacific Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 20: Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 21: Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 22: Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 23: China Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
    • Table 24:  China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 25: China Per Capita Net Disposable Income, 2015-2020, $
    • Table 26: China, Population By Age Group, 2015-2025, Thousands
    • Table 27: China GDP Per Capita, 2015-2020, $
    • Table 28: China, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 29: China Biologics Market Size, 2015-2025, $ Billion
    • Table 30: China Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 31: China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 32: China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 33: India Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 34: India Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 35: India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 36: India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 37: Japan Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 38: Japan Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 39: Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 40: Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 41: Australia Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 42: Australia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 43: Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 44: Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 45: Indonesia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 46: Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 47: Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 48: South Korea Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 49: South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 50: South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 51: Western Europe Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 52:  Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 53:  Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 54: Western Europe Per Capita Net Disposable Income, 2015-2020, $
    • Table 55: Western Europe, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 56: Western Europe GDP Per Capita, 2015-2020, $
    • Table 57: Western Europe, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 58: Western Europe Biologics Market Size, 2015-2025, $ Billion
    • Table 59: Western Europe Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 60: Western Europe Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 61: Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 62: Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 63: UK Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 64: UK Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 65: UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 66: UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 67: Germany Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 68: Germany Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 69: Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 70: Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 71: France Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 72: France Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 73: France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 74: France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 75: Eastern Europe Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
    • Table 76:  Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 77:  Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 78: Eastern Europe Per Capita Net Disposable Income, 2015-2020, $
    • Table 79: Eastern Europe, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 80: Eastern Europe GDP Per Capita, 2015-2020, $
    • Table 81: Eastern Europe, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 82: Eastern Europe Biologics Market Size, 2015-2025, $ Billion
    • Table 83: Eastern Europe Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 84: Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 85: Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 86: Russia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 87: Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 88: Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 89: North America Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
    • Table 90:  North America Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 91:  North America Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 92: North America Per Capita Net Disposable Income, 2015-2020, $
    • Table 93: North America, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 94: North America GDP Per Capita, 2015-2020, $
    • Table 95: North America, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 96: North America Biologics Market Size, 2015-2025, $ Billion
    • Table 97: North America Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 98: North America Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 99: North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 100: North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 101: USA Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
    • Table 102:  USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 103: USA Per Capita Net Disposable Income, 2015-2020, $
    • Table 104: USA, Population By Age Group, 2015-2025, Thousands
    • Table 105: USA GDP Per Capita, 2015-2020, $
    • Table 106: USA Home, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 107: USA Biologics Market Size, 2015-2025, $ Billion
    • Table 108: USA Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 109: USA Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 110: USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 111: USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 112: South America Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
    • Table 113:  South America Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 114:  South America Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 115: South America Per Capita Net Disposable Income, 2015-2020, $
    • Table 116: South America, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 117: South America GDP Per Capita, 2015-2020, $
    • Table 118: South America, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 119: South America Biologics Market Size, 2015-2025, $ Billion
    • Table 120: South America Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 121: South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 122: South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 123: Brazil Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 124: Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 125: Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 126:  Middle East Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 127:  Middle East Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 128: Middle East Per Capita Net Disposable Income, 2015-2020, $
    • Table 129: Middle East, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 130: Middle East GDP Per Capita, 2015-2020, $
    • Table 131: Middle East Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 132: Middle East Biologics Market Size, 2015-2025, $ Billion
    • Table 133: Middle East Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 134: Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 135: Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 136:  Africa Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 137:  Africa Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 138: Africa Per Capita Net Disposable Income, 2015-2020, $
    • Table 139: Africa, Population By Age Group, By Country, 2015-2025, Thousands
    • Table 140: Africa GDP Per Capita, 2015-2020, $
    • Table 141: Africa Healthcare Services Market Size, By Country, 2015-2025, $ Billion
    • Table 142: Africa Biologics Market Size, 2015-2025, $ Billion
    • Table 143: Africa Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 144: Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 145: Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 146: Global Pegfilgrastim Biosimilars Market, Key Competitor Estimated Market Shares, 2019 & 2020, Percentage (%)
    • Table 147: Sandoz (Novartis) – Financial Performance, 2016 – 2020, $ Billion
    • Table 148: Biocon – Financial Performance, 2016 – 2020, $ Billion
    • Table 149: Mylan – Financial Performance, 2016 – 2020, $ Billion
    • Table 150: Intas Biopharmaceuticals Ltd – Financial Performance, 2015 – 2019, $ Billion
    • Table 151: Dr. Reddy’s Laboratories – Financial Performance, 2016 – 2020, $ Billion
    • Table 152: Pfizer Inc. – Financial Overview, 2016 – 2020, $ Billion
    • Table 153: Emcure Pharmaceuticals – Financial Performance, 2016 – 2020, $ Billion
    • Table 154: Global Pegfilgrastim Biosimilars Market, Pipeline Analysis
    • Table 155: Global Pegfilgrastim Biosimilars Market Size Gain ($ Million), 2020 – 2025, By Country
    • Table 156: Global Pegfilgrastim Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2020 – 2025
    • Table 157: Global Pegfilgrastim Biosimilars Market Size Gain ($ Million), Segmentation By Distribution Channel, 2020 – 2025
    • Table 158: Pegfilgrastim Biosimilars - Market Data Sources

    List Of Figures

      Figure 1: Global Pegfilgrastim Biosimilars Market Segmentation By Application
    • Figure 2: Global Pegfilgrastim Biosimilars Market Segmentation By Distribution Channel
    • Figure 3: Global Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 4: Global Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 5: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 6: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 7: Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 8: Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 9: Asia-Pacific Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 10: Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 11: Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 12: China Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 13: China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 14: India Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 15: India Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 16: India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 17: Japan Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 18: Japan Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 19: Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 20: Australia Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 21: Australia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 22: Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 23: Indonesia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 24: Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 25: South Korea Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 26: South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 27: Western Europe Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 28: Western Europe Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 29: Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 30: UK Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 31: UK Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 32: UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 33: Germany Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 34: Germany Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 35: Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 36: France Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 37: France Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 38: France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 39: Eastern Europe Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 40: Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 41: Russia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 42: Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 43: North America Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 44: North America Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 45: North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 46: USA Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 47: USA Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 48: USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 49: South America Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 50: South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 51: Brazil Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 52: Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 53: Middle East Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 54: Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 55: Africa Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 56: Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 57: Global Pegfilgrastim Biosimilars Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
    • Figure 58: Global Pegfilgrastim Biosimilars Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
    • Figure 59 Sandoz (Novartis) – Financial Performance, 2016 – 2020, $ Billion
    • Figure 60: Biocon – Financial Performance, 2016 – 2020, $ Billion
    • Figure 61: Mylan – Financial Performance, 2016 – 2020, $ Billion
    • Figure 62: Intas Biopharmaceuticals Ltd – Financial Performance, 2015 – 2019, $ Billion
    • Figure 63: Dr. Reddy’s Laboratories – Financial Performance, 2016 – 2020, $ Billion
    • Figure 64: Pfizer Inc. – Financial Overview, 2016 – 2020, $ Billion
    • Figure 65: Emcure Pharmaceuticals – Financial Performance, 2016 – 2020, $ Billion
    Global Contract Research And Manufacturing Services (CRAMS) Market Size, Forecasts, And Opportunities – Includes CRAMS Market Overview
    Global Pulmonary Arterial Hypertension Market Overview And Prospects – Includes Pulmonary Arterial Hypertension Market Share
    Global Botanical Supplements Market Outlook, Opportunities And Strategies – Includes Botanical Supplements Industry
    Global Pharmacovigilance Market Size, Forecasts, And Opportunities – Includes Pharmacovigilance Market Share
    Global Herbal Supplements Market Outlook, Opportunities And Strategies – Includes Herbal Supplements Market Size
    Global Hyperphosphatemia Treatment Market Outlook, Opportunities And Strategies – Including Hyperphosphatemia Treatment Algorithm
    Global Multivitamin Capsules And Tablets Market Size, Forecasts, And Opportunities – Includes Vitamin Industry Trends
    Global Naloxone Spray Market Overview And Prospects – Including pharmacies
    Biosimilar Monoclonal Antibodies Global Market Report 2022 – By Type (Synthetic Chemicals, Biopharmaceuticals), By Application (Chronic & Autoimmune Diseases, Oncology), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab) – Market Size, Trends, And Global Forecast 2022-2026
    View Report
    Biosimilar Therapeutic Peptides Global Market Report 2022 – By Route Of Administration (Parenteral Route, Transdermal Route), By Application (Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders), By Type (Innovative, Generic) – Market Size, Trends, And Global Forecast 2022-2026
    View Report
    Rituximab Biosimilars Global Market Report 2022 – By Application (Non-Hodgkin's Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By Route Of Administration (Subcutaneous, Intravenous, Molecular Type) – Market Size, Trends, And Global Forecast 2022-2026
    View Report
    Biosimilar Hormones Global Market Report 2022 – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Speciality Clinics) – Market Size, Trends, And Global Forecast 2022-2026
    View Report
    Biosimilar Lymphocyte Modulator Global Market Report 2022 – By Drug (Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar), By Disease (Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis) – Market Size, Trends, And Global Forecast 2022-2026
    View Report
    Biosimilars Global Market Report 2022 – By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Types (Human Growth Hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases) – Market Size, Trends, And Global Forecast 2022-2026
    View Report
    Oncology Biosimilars Global Market Report 2022 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2022-2026
    View Report
    Filgrastim Biosimilars Market - By Application (Oncology, Chronic and Autoimmune Diseases, Blood disorders, Growth hormone deficiency), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), And By Region, Opportunities And Strategies – Global Filgrastim Biosimilars Market Forecast To 2030
    View Report